HomeBUSINESS
BUSINESS

Positive RA Data Out for JAK Inhibitor Peficitinib, Astellas Gears Up for Filing
(Feb.9.2018)

Astellas Pharma said on February 8 that its JAK inhibitor peficitinib (ASP015K) achieved primary endpoints in two PIII studies covering rheumatoid arthritis (RA) patients inadequately controlled with existing therapies. With the latest data, the Japanese giant will now prep for filing in Japan and other Asian markets ...
(LOG IN FOR FULL STORY)

News Calendar